TTrialPathMatch Me to Trials
← Back to trials
RecruitingAtopic Dermatitis

A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants

Eligible age

18–70 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a randomized, double-blind, placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of SKB575. This study consists of two parts. Phase Ia is a single ascending dose study in healthy subjects and Phase Ib is a proof-of-concept study in patients with moderate to severe atopic dermatitis.

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

You may qualify if…

  • ✓ Phase Ia healthy participants must meet all of the following inclusion criteria to be enrolled:
  • ✓ 1. The participant is able to understand and comply with the requirements of the study and voluntarily signs the informed consent form.
  • ✓ 2. Age at the time of signing the informed consent form is 18-55 years (inclusive), any gender.
  • ✓ 3. Male participants weigh ≥ 50.0 kg, female participants weigh ≥ 45.0 kg; body mass index \[BMI\] is 18.0-28.0 kg/m² (inclusive).
  • ✓ 4. No clinically significant abnormalities.
  • ✓ Phase Ib participants with moderate to severe AD must meet all of the following inclusion criteria to be enrolled:
  • ✓ 1. The participant is able to understand and comply with the requirements of the study and voluntarily signs the informed consent form.
  • ✓ 2. Age at the time of signing the informed consent form is 18-70 years (inclusive), any gender.

You may not qualify if…

  • ✕ 1. History of any clinically significant disease of the cardiovascular, hematological, hepatic, renal, digestive, neurological, respiratory, or psychiatric systems, or metabolic disorders, or any other disease or physiological condition that may interfere with the trial results.
  • ✕ 2. History of malignancy, regardless of whether treated, and regardless of the presence or absence of signs of local recurrence or metastasis.
  • ✕ 3. Presence of skin scars, induration, inflammation, edema, ulceration, infection, bleeding, or other conditions at the intended injection site that are unsuitable for subcutaneous injection.
  • ✕ 4. Clinical signs of active infection within 4 weeks prior to randomization, including but not limited to urogenital infection, pulmonary infection, acute sinusitis, appendicitis, bloodstream infection, etc.
  • ✕ 5. History of tuberculosis or complications of tuberculosis, or positive/abnormal findings of clinical significance based on chest X-ray/chest CT, physical examination, and T-cell interferon-gamma release assay (TIGRA) (e.g., T-Spot or Quanti-FERON®-TB Gold™).
  • ✕ 6. Subjects positive for Hepatitis B (HBsAg, HBeAg, HBeAb, or HBcAb), positive for Hepatitis C antibody, positive for HIV antibody, or positive for syphilis serology.
  • ✕ NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Source: ClinicalTrials.gov · NCT07488065 · last updated 2026-05-08

A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atop · TrialPath